Vinquamin - instructions for use, doses, side effects, contraindications

Clinical and pharmacological group: & nbsp

Included in the formulation

АТХ:

C.05 Angioprotectors

C.04 Peripheral vasodilators

Pharmacodynamics:

Means that improve cerebral circulation. The alkaloid is a small vinca plant (Vinca minor), a family of cotta plants (Apocynaceae). Increases cerebral blood flow and oxygen utilization by brain tissue, reduces and stabilizes the resistance of the cerebral vascular bed. Has hypotensive, antispasmodic and sedative effect. Increases mental performance, improves memory.

Pharmacokinetics:

After oral administration, it is rapidly absorbed. Bioavailability is 70%. The maximum concentration in the blood plasma is reached after 1 hour. Metabolized in the liver with the formation of inactive metabolites. Half-life - 5 o'clock. Excreted mainly by the kidneys.

Indications:

Violation of cerebral circulation (in t.ch. after ischemic stroke; with craniocerebral trauma, atherosclerotic changes in the cerebral vessels, post-mortem craniocerebral hypertension), spasm of cerebral vessels, migraine, dizziness, absent-mindedness, speech impairment, vestibular and labyrinthine disturbances of vascular genesis; neurogenic sinus tachycardia, arterial hypertension (initial forms); diabetic angiopathy; memory impairment and decreased intellectual abilities in elderly patients,slow development of intellectual abilities in children and adolescents; violation of concentration, coordination of movements in mental illness (combination therapy).

ICD-10

VI.G40-G47.G43 Migraine

V.F70-F79 Mental retardation

V.F00-F09.F07 Personality and behavioral disorders due to illness, damage or dysfunction of the brain

VII.H30-H36.H35.0 Background retinopathy and retinal vascular changes

VIII.H80-H83.H81 Violations of the vestibular function

VIII.H90-H95.H93.0 Degenerative and vascular diseases of the ear

IX.I10-I15.I10 Essential [primary] hypertension

IX.I60-I69.I67.2 Cerebral atherosclerosis

XIX.T90-T98.T90 Consequences of head injuries

Contraindications:

Tumor of the brain, ischemic heart disease, arrhythmias, arterial hypotension, pregnancy, lactation, hypersensitivity to vinkin.

Carefully:

With caution appoint patients with hypertension, as well as those who underwent myocardial infarction.

Pregnancy and lactation:

Contraindicated in pregnancy. For the duration of treatment, breastfeeding should be discontinued.

Dosing and Administration:

Inside, regardless of food intake, 10-40 mg 3 times a day, if necessary, increase the dose to 40 mg 4 times a day. The course of treatment is 10-30 days.The maintenance dose is 20 mg 1-2 times a day. Children 6 years and older - 5 mg 3 times a day.

Intravenously drip or intramuscularly, 15 mg 1-2 times a day; children 6 years and older - 7.5 mg 2 times a day. The course of treatment is about 2 months.

Side effects:

From the cardiovascular system: lowering of blood pressure, tachycardia.

Allergic reactions: skin rash.

Overdose:

Treatment is symptomatic. There is no specific antidote.

Interaction:

Contraindicated the combination of 4-nitro-N - [(1RS) -1- (4-fluorophenyl) -2- (1-ethylpiperidin-4-yl) ethyl] benzamide hydrochloride with vincamine, potentially capable of causing polymorphic ventricular tachycardia.

Contraindicated joint use of amisulpride with vincamin (intravenously), capable of extending the interval QT and cause a paroxysmal tachycardia, including a potentially lethal polymorphic ventricular tachycardia.

Combined use of indapamide (in combination vinpocetine + indapamide + metoprolol + enalapril) and wincamine in the form of forms for intravenous introduction requires special attention: an increased risk of ventricular arrhythmias, especially arrhythmias such as "pirouette" (risk factor - hypokalemia).It is necessary to monitor the potassium content in blood plasma and, if necessary, adjust it before the initiation of combination therapy with indapamide (in combination vinpocetine + indapamide + metoprolol + enalapril) and wankamine in the form of forms for intravenous introduction. It is necessary to monitor the clinical condition of the patient, the content of plasma electrolytes, electrocardiograms. In patients with hypokalemia in combination therapy, it is necessary to apply medicines, not causing arrhythmia.

Because of the risk of developing hypokalemia, caution is required when hydrochlorothiazide is used simultaneously (as part of a combination hydrochlorothiazide + olmesartan medoxomil) with a winch for intravenous administration, capable of causing arrhythmia.

Vincamine in combination with indapamide (in combination indapamide + enalapril) can lead to the development of arrhythmia.

Special instructions:

Care should be taken when using rilmenidine with vincamaine at the same time.

Instructions

Winkamine (Vincaminum)